EDH AND TERTHERA ENTERS INTO EXCLUSIVE DISTRIBUTION AGREEMENT FOR TERBIUM-161

Agreement will enable a swift introduction of Tb-161 into Türkiye, Bulgaria and Azerbaijan, enabling the application of a novel radiopharmaceutical for cancer healthcare.

BREDA, 17 October 2023 – EDH Nükleer Tıp & Sağlık Hizmetleri (“EDH”), a trailblazer in the domain of radiopharmacy and nuclear medicine,and TerThera BV are pleased to announce the signing of an exclusive distribution agreement for the regions Türkiye, Bulgaria and Azerbaijan.

Terbium-161, a carrier free lanthanide produced by neutron activation, is a highly promising radionuclide for Radioligand Therapy (RLT) exhibiting comparable chemical characteristics to known radiolanthanides that has the potential, due to highest addition of Auger electronic emission with a higher linear energy transfer, to improve anti-tumor capabilities for primary and (micro)metastasized cancers. EDH took the initiative to first introduce Terbium-161 into Türkiye enabling both preclinical and clinical research.

“I am absolutely thrilled about this collaboration with our esteemed partners at Terthera. Their invaluable contributions and expertise have played a pivotal role in bringing this groundbreaking technology to fruition.The potential of this partnership is truly unparalleled, and though there’s an ambitious journey ahead, the future shines brilliantly clear before us”. said Hasan Ulaş Özcan, General Manager of EDH. “I also want to express my heartfelt gratitude to our exceptional team at EDH. Their hard work, dedication, and unwavering commitment have been instrumental in making this collaboration with Terthera a reality. Together, we are forging a path toward an incredibly promising future”

Not only will EDH further increase their efforts to make Terbium-161 widely available in each region but will greatly support in the generation of dire needed clinical evidence for the application of Terbium-161 for RLT that will be shared in time with the global community of the Nuclear Medicine.

“In both my professional and private life, I have always had a warm heart towards Türkiye. It is a fantastic country with a very strong presence in nuclear medicine. One of the first countries to widely adopt Ga-68 PET diagnostics and RLT. We are seeing a bright future in our collaboration with EDH, a company with a long and fruitful experience in the nuclear medicine industry” said Philippe van Overeem, CEO of TerThera. “The ideas EDH initiated to launch Tb-161 in Türkiye, Azerbaijan and Bulgaria are truly remarkable and we foresee a very fruitful and long term relationship”

About TerThera BV

TerThera is a radionuclide production focussed company based in The Netherlands. The founders and staff of TerThera have decades of experience in the nuclear medicine industry and are giving their full focus on the production of the innovative radionuclide Terbium-161 (Tb-161). TerThera is building a global platform to meet the growing demand for radionuclides in oncology and nuclear medicine.

About EDH

EDH stands as a preeminent leader in radiopharmacy and nuclear medicine, offering a comprehensive range of services encompassing cutting-edge device sales and after-sales support, radiopharmaceutical distribution, and turn-key project consultancy. With over a decade of experience, EDH possesses proprietary expertise in emerging technologies, regulatory compliance, and industry networking, ensuring clients access the forefront of innovation and compliance in the dynamic field of radiopharmacy and nuclear medicine.

For more information